Skip to main content

Reduced expression of both Bax and Bcl-2 is independently associated with lymph node metastasis in human breast carcinomas

Buy Article:

$43.00 plus tax (Refund Policy)

Imbalance between pro-apoptotic and anti-apoptotic proteins, causing altered apoptosis, may lead to tumour development and tumour progression, and reduced response to adjuvant therapy. In this study, we evaluated the expression patterns of Bcl-2, Bcl-xL, and Bax protein in 126 primary invasive breast carcinomas, and the association with other clinicopathological parameters. We used immunohistochemical methods to evaluate protein expression. Reduced expression of both Bax and Bcl-2 was associated with lymphnode metastases in univariate analyses (one-way ANOVA) as well as in multivariate analysis (binary logistic regression) (Bcl-2 p=0.003 univariate, p=0.01 multivariate, Bax p=0.05 univariate, p=0.03 multivariate). Bcl-2 overexpression showed an inverse association with cyclin A (p=0.05), while expression of Bcl-xL showed an association only with cyclin D3 (p=0.04). Bcl-xL expression also showed a highly significant association with oestrogen receptor status (p=0.009). Bcl-2 and Bcl-xL showed an association with different D-type cyclins, indicating different pathways of pathogenesis. Expression of Bcl-2 was associated with better patient survival in univariate analysis (Kaplan meyer p=0.04), but lost its prognostic value in multivariate analysis (Cox regression p=0.2).
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Bax, Bcl-2, Bcl-xL; apoptosis; breast carcinomas; immunohistochemistry

Document Type: Research Article

Affiliations: 1: Department of Surgery, and 2: Institute of Clinical Molecular Biology, Akershus University Hospital,1474 Nordbyhagen, Norway 3: Department of Pathology, the Norwegian Radium Hospital, University of Oslo, Oslo, Norway

Publication date: 2002-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more